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Abstract
The 2005 National Institutes of Health (NIH) consensus criteria for chronic graft-versus-host 
disease (cGVHD) have set standards for reporting. Many questions, however, have arisen 
regarding implementation and utilization. To identify perceived areas of controversy, we 
conducted an international survey on diagnosis and scoring of cGVHD. Agreement was observed 
for 50% to 83% of the 72 questions in 7 topic areas. There was agreement in the need for 
modifying criteria in 6 situations: 2 or more distinctive manifestations should be enough to 
diagnose cGVHD, symptoms not due to cGVHD should be scored differently, active disease and 
fixed deficits should be distinguished, a minimum threshold body surface area of hidebound skin 
involvement should be required for a skin score 3, asymptomatic oral lichenoid changes should be 
considered a score 1, and lung biopsy should be unnecessary to diagnose cGVHD in a patient with 
bronchiolitis obliterans as the only manifestation. The survey also identified 26 points of 
controversy. Whenever possible, studies should be conducted to confirm the appropriateness of 
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any revisions. In cases where data are not available, clarification of the NIH recommendations by 
consensus is necessary. This survey should inform future research in the field and revisions of the 
current consensus criteria.
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INTRODUCTION
Chronic graft-versus-host disease (GVHD) is an immune-mediated disorder that occurs in 
30–50% of patients after allogeneic hematopoietic cell transplantation (HCT).1–3 Chronic 
GVHD causes significant late morbidity and mortality and affects quality of life, survival 
and other transplant outcomes. In 2005, the National Institutes of Health (NIH) convened an 
expert conference to develop consensus on criteria for diagnosis, staging, pathology, 
biomarkers, response measurement, supportive care and design of clinical trials.4–9 The 
major goal of the consensus project was to develop a “standardized common language” 
among investigators focused on chronic GVHD in order to facilitate comparisons between 
clinical studies. While many studies have reported the validity of the Consensus 
criteria,10–27 implementation of the criteria in daily work has raised many practical 
questions.28, 29 Participants in the Conference anticipated that the advent of new data and 
experience applying the criteria to actual clinical situations may necessitate clarifications, 
corrections, refinement and perhaps revisions of the criteria.
The goals of this survey were to identify areas of confusion or disagreement with the NIH 
criteria particularly for diagnosis and severity scoring of chronic GVHD. We generated a 
questionnaire based on queries collected from various sources, and conducted a detailed 
survey among a voluntary group of international investigators who are interested in chronic 
GVHD research. The results of this survey should help to determine the next steps for 
research activities aiming to refine or modify the consensus criteria for chronic GVHD.
METHODS
Survey
Since the 2005 NIH Consensus Conference, the authors have collected frequently asked 
questions (FAQs) about the NIH consensus recommendations from various sources. Most 
FAQs came from health care professionals throughout the world, and some arose in the 
context of clinical trials. Two of the authors (Y.I. and S.J.L.) reviewed all collected FAQs 
and summarized them into 72 questions (Supplementary Appendix). Questions were 
formatted to elicit opinions about best practices for the future rather than asking how 
respondents are applying the current NIH recommendations. Two other authors (M.J. and 
S.P.) critically reviewed the draft question list and took the survey to establish the 
anticipated completion time before the questionnaire was finalized. An invitation to 
complete the survey was sent to 64 members of the International Chronic GVHD Special 
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Interest Group in February 2013, with two e-mail reminders sent 2 weeks and 3 weeks after 
the survey invitation. The International Chronic GVHD Special Interest Group is a voluntary 
group of investigators who are interested in chronic GVHD research. The group is organized 
by one of the authors (S.J.L.) and anyone can participate in the group by emailing their 
interest to chronicGVHDstudies@fhcrc.org. A web-based survey (Survey Monkey) was 
used to collect responses over a 5 week period. The invitation included information about a 
chance to win two $500 gift cards for respondents who completed the survey by the 
deadline. The study protocol was approved by the Institutional Review Board of the Fred 
Hutchinson Cancer Research Center.
Definition of agreement in survey answers
Agreement for each question was considered high when ≥80% respondents chose the same 
answer, and was considered moderate when ≥60% but <80% respondents chose the same 
answer. Agreement was considered controversial when <60% respondents chose the same 
answer. Three questions that had multiple components (Q10, Q14, Q19) are reported 
according to the agreement level for each component.
Analyzed topic areas
Analysis was performed according to seven clinically relevant topic areas in the 
questionnaire (Table 1). Fourteen questions asked specifically whether the current NIH 
recommendations should be revised.
1. What are diagnostic (pathognomonic) and distinctive (suggestive of, but requiring 
histopathologic or additional testing for confirmation) criteria for chronic GVHD 
(21 questions)
2. Can pathology discriminate chronic GVHD from other causes? (6 questions)
3. Is biopsy necessary to diagnose chronic GVHD in certain organs? (5 questions)
4. How should severity of chronic GVHD be scored? (23 questions)
5. Should manifestations not due to GVHD be included in the scoring? (8 questions)
6. Some organs are scored in multiple ways. How should discrepancies between 
different evaluations be handled? (8 questions)
7. When the current NIH recommendations lack clarity or are silent about particularly 
clinical situations, how should they be scored? (8 questions)
RESULTS
Survey response and characteristics of participants
A total of 48 (75%) of 64 invited investigators completed the survey within 5 weeks after 
the survey was opened. Six (13%) respondents had 3–5 years of experience in caring for 
patients with chronic GVHD, 14 (29%) had 6–10 years, 15 (31%) had 11–20 years, and 11 
(23%) had more than 20 years of experience. Forty-four (92%) of respondents were 
physicians and 40 (83%) considered themselves as experts in management of chronic 
GVHD. Respondents were from North America (67%), Europe (15%), South America 
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(10%), Asia (6%) and the Middle East (2%). The raw results of the survey are provided in 
Supplementary Appendix.
Agreement in answers according to topic areas
At least moderate agreement was observed for 50% to 83% of questions according to topic 
areas (Figure 1). High agreement was most frequently observed in responses to questions 
about the method of scoring symptoms not due to GVHD, where respondents clearly 
favored distinguishing symptoms based on whether they were attributable to chronic 
GVHD. Controversies were most frequently observed in responses to questions prompted by 
lack of clarity in the current NIH consensus, where respondents seemed to apply their own 
interpretations to the presented scenarios. Detailed results according to topic areas are shown 
in Table 1.
Opinions regarding revision of the current NIH recommendations
Among the 14 questions that asked whether the current NIH recommendations should be 
revised (Table 1), respondents agreed that recommendations should be revised in 6 points 
and should not be revised in 4 points. Opinions were controversial for 4 questions. The 6 
points that respondents agreed with needing revision included the following:
High agreement
1 Two or more distinctive manifestations should be diagnostic of chronic GVHD.
2 Symptoms clearly not due to GVHD should be scored differently.
3 Active disease and fixed deficits should be distinguished when organ severity is 
scored.
Moderate agreement
4 A minimum threshold of body surface area involvement is required to score a 
skin severity of 3 for hidebound skin changes.
5 The mouth score should be score 1 if asymptomatic patients have diagnostic 
signs.
6 Clinical bronchiolitis obliterans syndrome without lung biopsy should be 
considered a diagnostic manifestation.
Summaries of answers for each topic
Topic 1: What are diagnostic and distinctive criteria for chronic GVHD?—
Respondents agreed that two or more distinctive manifestations should be sufficient for the 
diagnosis of chronic GVHD, that only one site with acute manifestations is enough to put a 
patient with chronic GVHD in the “overlap” category, and that “overlap” chronic GVHD 
and “progressive onset” are not interchangeable terms. Respondents agreed that the 
gastrointestinal (GI) and hepatic manifestations typically observed with acute GVHD are not 
distinctive for chronic GVHD. Respondents agreed that ocular dryness very early after 
transplantation should not be diagnosed as acute or chronic GVHD, and that clinical 
bronchiolitis obliterans syndrome (i.e., documented by pulmonary function tests and image 
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studies with negative work up for pathogens) should be considered a diagnostic 
manifestation without the need for confirmation by lung biopsy.
Many issues related to diagnostic and distinctive manifestations were controversial. For 
example, whether there were any diagnostic features for the eyes, liver and GI tract other 
than esophagus, whether classification of late acute GVHD and overlap chronic GVHD 
should be determined only by the current condition or by the history of chronic GVHD, 
whether gingivitis, oral mucositis and pain should remain as common signs seen in both 
acute and chronic GVHD, and whether joint pain mimicking rheumatoid arthritis is a 
manifestation of GVHD. Controversy also arose in the question of whether cryptogenic 
organizing pneumonia should remain a common sign of GVHD, should be a distinctive sign 
of chronic GVHD, or should be removed as a manifestation of GVHD.
Topic 2: Can pathology discriminate chronic GVHD from other causes?—
Respondents agreed that pathology was able to distinguish chronic GVHD from acute 
GVHD or other etiologies in the skin, lung, mouth and muscle but not in the liver and GI 
tract other than esophagus. Usefulness of pathology in distinguishing chronic GVHD in the 
fascia, esophagus and genital tract was controversial. We did not ask whether pathology 
could distinguish different infections.
Topic 3: Is biopsy necessary to diagnose chronic GVHD in certain organs?—
Respondents agreed that biopsy was not always necessary to confirm chronic GVHD in the 
skin, liver and GI tract if the patient had diagnostic chronic GVHD in other sites. 
Respondents agreed that diarrhea should be scored as chronic GVHD even for negative 
biopsy results in patients with chronic GVHD. It was controversial whether gastrointestinal 
biopsy was necessary to confirm GVHD in patients with upper GI symptoms.
Topic 4: Should criteria for severity scoring of chronic GVHD be revised?—
Respondents agreed that fixed deficits and active chronic GVHD should be distinguished 
when manifestations are scored, but it was controversial whether revisions should be made 
for both severity scoring and response measurement or only for response measurement. The 
current consensus does not clearly specify whether manifestations other than the eight core 
sites (skin, mouth, eyes, lung, liver, GI tract, joints and fascia and genital tract) should be 
included in the global scoring system. Respondents agreed esophageal stricture, 
thrombocytopenia, and pericardial or pleural effusion but not cardiac complications should 
be included, although they remain difficult to score. Inclusion of performance status and 
other manifestations was controversial. For the skin, respondents agreed that maculopapular 
rash, lichenoid features, erythroderma, sclerosis, erythema, papulosquamous lesions or 
ichthyosis, poikiloderma, keratosis pilaris and hair involvement should all be considered 
when determining the skin score, while controversy arose in the question of whether hypo or 
hyper-pigmentation, pruritus and nail involvement should be considered when determining 
the skin score as currently recommended. Respondents agreed that hidebound changes 
should not be rated as a skin score 3 if the body surface area affected was minimal, and that 
the mouth score 1 should be revised so that it includes asymptomatic lichenoid changes that 
are currently scored as 0. Respondents reaffirmed the current NIH recommendations that 
mechanical interventions for dry eye such as punctual plugging and corneal lenses, and 
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visual impairment should be considered in the eye severity score. The use of a dilator for 
vaginal stricture in the absence of symptoms as an indicator of severe involvement was 
controversial.
Topic 5: Should manifestations not due to GVHD be included in the scoring?
—Overall, respondents agreed that symptoms clearly attributable to causes other than 
GVHD should not be scored. For example, respondents agreed that eye, joint or fascia and 
lung manifestations should not be scored if they predated transplantation and were stable. In 
cases where clinicians are not sure of the etiology, respondents agree that symptoms should 
be included in the chronic GVHD scoring. It was controversial whether the score should be 
downgraded by a 1 point from the actual score when other proven etiologies were present.
Topic 6: How should discrepancies between different evaluations be 
handled?—For the skin, eyes, lung and genital tract, respondents agreed with the use of 
the worst manifestation when the patient had discrepant findings in different areas rather 
than using the lesser or average score. For the lung, respondents agreed that pulmonary 
symptoms should be scored 0 if pulmonary function tests were normal, although the current 
consensus recommended taking the higher of the symptom and pulmonary function test 
score. Answers for the mouth and liver were controversial.
Topic 7: When the current NIH recommendations lack clarity or are silent 
about particularly clinical situations, how should they be scored?—Despite lack 
of clear guidance in some of the consensus recommendations, agreement in opinions was 
observed for half of the questions. Respondents agreed that erectile dysfunction is not a 
GVHD manifestation, that some eye drops such as antibiotics and glaucoma medications 
should not be included for the eye score based on the frequency of eye drop use, and that all 
liver function tests including serum bilirubin, alanine aminotransferase, aspartate 
aminotransferase and alkaline phosphatase should be considered in staging late acute GVHD 
of the liver. Controversies were related to duration of resolution required for the “recurrent” 
GVHD category, the reference time point used for calculation of weight loss as a 
manifestation of GI involvement, and the methods used to evaluate patients when pulmonary 
function tests or gynecological exam results were missing.
DISCUSSION
In the past, studies of chronic GVHD have been compromised by lack of standardized 
diagnosis, grading and response assessment of chronic GVHD. The 2005 NIH Consensus 
Conference provided a common language and set of criteria, but clinical experience with the 
recommendations has exposed some areas of ambiguity that need clarification. Although 
agreement rates varied according to topic areas, at least moderate agreement was observed 
for ≥50% of questions addressing these areas, suggesting that consensus can be reached on 
these issues.
For the most part, the controversial areas would not substantially change interpretation of 
the scoring or response criteria. However, two main areas where respondents disagreed with 
the current NIH recommendations (the rules for scoring symptoms not due to GVHD and 
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lack of distinction between active disease and fixed deficits) might have a major impact on 
scoring depending on the number of other conditions contributing to the organ 
abnormalities. This question was discussed during the 2005 Consensus Conference, and it 
was decided that incorporating considerations of attribution or reversibility would 
complicate severity scoring as no reliable definitions of reversibility existed. The results of 
our survey show that real-world experience has led to discontent with the inability to include 
these considerations when scoring severity. Future studies should focus on clarifying these 
areas as they are critical to both severity scoring and response measurement. To account for 
manifestations not due to GVHD, scores may be down-graded in a manner similar to the 
modified scoring for acute GVHD.30 Since such an adjustment for concomitant diseases 
might result in increased heterogeneity in severity grading, this approach requires validation. 
To account for the distinction between activity and fixed deficits, an activity score for 
chronic GVHD could be developed, similar to the Systemic Lupus Erythematosus Disease 
Activity Index31 or Crohn’s Disease Activity Index.32 Identification and validation of 
biomarkers to distinguish active and inactive chronic GVHD would be very useful since 
these situations may be indistinguishable by physical exam.
Other issues where respondents disagreed with current NIH recommendations are the need 
for lung biopsy to diagnose bronchiolitis obliterans when they do not have other 
manifestations of chronic GVHD. Many clinicians recognize the risk and difficulty of lung 
biopsy for diagnosis of bronchiolitis obliterans and are not willing to subject patients to such 
risks. Similar topics were discussed at the 2009 European meeting29 and at the 2012 BMT 
Tandem Meetings.28
Another disagreement is with the rule for scoring the mouth as a 0 for asymptomatic 
lichenoid changes. This was based on the assumption that activities of daily living would not 
be affected by asymptomatic oral lichenoid changes and therefore they should be scored as a 
0 in severity assessment. In addition, systemic treatment is often not indicated if oral 
lichenoid changes are the sole manifestation of chronic GVHD. On the other hand, if 
isolated lichenoid changes are not captured in organ scoring, the association of these 
changes with long-term sequela including secondary oral cancer would be missed.33 
Directed studies are warranted to determine the appropriateness of modifying the rule for 
scoring the mouth, since changes in the current mouth score correlated well with both 
clinician and patient-perceived response in oral GVHD.26
Many of the controversial issues were identified because they are common situations in 
clinical practice but the current NIH recommendations are unclear or lack guidance. For 
example, “recurrent” late acute GVHD is defined as development of acute GVHD beyond 
day 100 after prior acute GVHD has resolved, but the number of GVHD-free days required 
to be considered “recurrent” versus “persistent” has never been defined. Another example is 
the chronic GVHD GI severity score, which is based in part on the percentage of weight 
loss, although the reference time point is not specified. A routine gynecological examination 
for patients with chronic GVHD is required, since manifestations of genital GVHD are not 
always reported and are not captured unless the physical exam includes the genitalia. On the 
other hand, rules for scoring in the absence of gynecological examination should be given. 
The results of the survey also highlight the need for developing a consensus about 
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histopathology and biomarkers of liver GVHD since clinical and laboratory findings are not 
diagnostic. Given the current lack of empirical data, evidence-based resolution is not 
possible. Efforts should be made to design appropriate studies to address those questions. 
Provisional consensus could be reached in other cases where need for clarifications is urgent 
or obvious.
This study has some limitations. First, results were derived from a relatively small group of 
committed investigators. Mitigating this concern is that respondents are from various 
international regions, half have more than 10 years’ experience of caring patients with 
chronic GVHD, many report they use the NIH criteria in clinical practice, and most have 
extensive experience with clinical trials in chronic GVHD. Thus, the results of this study 
should provide meaningful opinions. Second, we could not evaluate differences in answers 
according to investigators’ regions or experience including years in practice and the number 
of patients they have seen because of limited numbers of participants.
In summary, this survey highlights areas of controversies that were not anticipated by the 
NIH criteria or where additional clinical experience has led investigators to question the 
original recommendations. These results will be useful guidance for revisiting the NIH 
consensus criteria, and a conference is planned in June 2014. In situations where sufficient 
data are available, revisions of the current recommendations will be made. In situations 
where additional information is needed, studies should be performed to collect these data. 
For other situations where data cannot be generated and recommendations are truly based on 
opinions, the goal should be to achieve a clear consensus to ensure standardized use of the 
criteria.
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Table 1
Agreement level according to topic areas
Topic 1: What are diagnostic and distinctive criteria for chronic GVHD?
Agreement level Agreed answer or controversial question Category
High* (R)
Two or more distinctive manifestations should be considered sufficient to diagnose chronic 
GVHD. (Q3) Diagnosis
High Only one site with acute manifestations (skin, liver or GI) is enough to diagnose “overlap” chronic GVHD. (Q5) Subcategory of GVHD
High Overlap chronic GVHD and progressive onset are NOT interchangeable terms. (Q8) Subcategory of GVHD
High It is difficult to distinguish deep from superficial sclerosis in the abdominal skin among obese patients. (Q23) Skin
High By careful history taking and physical examination of fascia and joints, you can distinguish joint problems related to chronic GVHD from other cause of joint impairment. (Q53) Joint/fascia
High Nephrotic syndrome after allogeneic transplantation should be considered a manifestation of chronic GVHD. (Q72) Other sites
Moderate* (NR) There should be no distinctive features of chronic GVHD for the GI tract and liver. (Q2) Diagnosis
Moderate* (NR)
There should be no pediatric modifications to the categorizations of diagnostic and distinct 
manifestations. (Q4) Diagnosis
Moderate* (NR) It is not necessary to revise the terms “acute” and “chronic” GVHD to something else. (Q6) Subcategory of GVHD
Moderate There are no imaging methods that can help to distinguish deep from superficial sclerosis. (Q24) Skin
Moderate
Neither acute nor chronic GVHD should be diagnosed for a patient who had ocular dryness very 
early after transplantation (for example, 30 days after transplantation), with no other 
manifestations of chronic GVHD. (Q26)
Eye
Moderate Isolated early fasciitis manifested by edema is diagnostic for chronic GVHD. (Q52) Joint/fascia
Moderate* (R)
Clinical bronchiolitis obliterans syndrome should be considered a diagnostic manifestation 
(sufficient to make the diagnosis of chronic GVHD). (Q56) Lung
Controversial*
Currently, there are no diagnostic features of chronic GVHD for the eyes, liver and GI tract 
except esophagus. Should there be? (Q1) Diagnosis
Controversial
Do you categorize the following patient as late acute GVHD or overlap chronic GVHD? The 
patient had overlap chronic GVHD (oral lichenoid changes and gut GVHD). All manifestations 
were completely resolved after six months of systemic treatment. Now 2 years after 




If a patient has “new ocular sicca documented by Schirmer test” or “a new onset of 




Should gingivitis, oral mucositis and pain continue to be considered “common” signs, even if 
mouth is not a recognized target organ in acute GVHD? Or should these be considered 
distinctive signs of chronic GVHD? (Q40)
Mouth
Controversial Do you think joint pain mimicking rheumatoid arthritis after transplant is joint GVHD? (Q54) Joint
Controversial Is cryptogenic organizing pneumonia a form of lung GVHD? (Q57) Lung
Controversial*
Should cryptogenic organizing pneumonia still be considered a “common” sign, since lung is 
not a recognized target organ in acute GVHD? (Q58) Lung
Controversial How do you determine if peripheral neuropathy is due to chronic GVHD in a patient with an established diagnosis of chronic GVHD? (Q71) Other sites
Topic 2: Can pathology discriminate chronic GVHD from other causes?
Agreement level Agreed answer or controversial question Category
High Pathologists can NOT distinguish between acute and chronic GVHD in the liver. (Q10) Pathology
High Pathologists can NOT confidently diagnose liver chronic GVHD. (Q11) Pathology
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Topic 1: What are diagnostic and distinctive criteria for chronic GVHD?
Agreement level Agreed answer or controversial question Category
Moderate Pathologists can NOT distinguish in GI tract except for esophagus. (Q10) Pathology
Moderate Pathologists can distinguish between acute and chronic GVHD in the skin, lung and mouth. (Q10) Pathology
Moderate If muscle biopsy is positive for myositis but diagnostic or distinctive features of chronic GVHD are absent in other sites, it should be sufficient to diagnose chronic GVHD. (Q55) Muscle
Controversial Pathologists can distinguish between acute and chronic GVHD in fascia, esophagus, and genital tract. (Q10) Pathology
Topic 3: Is biopsy necessary to diagnose chronic GVHD in certain organs?
Agreement level Agreed answer or controversial question Category
High* (NR) Skin biopsy is NOT mandatory for diagnosis of skin chronic GVHD. (Q16) Skin
High If a patient with already diagnosed chronic GVHD has LFT abnormalities but no liver biopsy, LFT abnormalities should be considered GVHD. (Q49) Liver
Moderate We should score diarrhea in the NIH GI scoring section when the patient has chronic GVHD in other sites but biopsy is negative for GI GVHD. (Q42) GI
Moderate Diarrhea should be scored as GI GVHD if no biopsy is done but a patient has diagnostic chronic GVHD in other sites. (Q43) GI
Controversial A patient has chronic GVHD in other sites plus nausea and anorexia. Is a biopsy required for the diagnosis of GI involvement? (Q44) GI
Topic 4: How should severity of chronic GVHD be scored?
Agreement level Agreed answer or controversial question Category
High Cardiomyopathy, cardiac conduction defects, and coronary artery involvement should NOT be included in the global scoring system. (Q14) Global score
High* (R)
We should revise the current consensus that recommends rating organ severity without 
distinguishing between active disease and fixed deficits. (Q15) Response
High
Maclopapular rash, lichen planus-like feature, erythroderma, sclerotic features, erythema, 
papulosquamous lesions or ichthyosis and poikiloderma should be considered for calculating 
body surface area (BSA). (Q19)
Skin
High Pruritus should NOT be considered for calculating BSA. (Q19) Skin
High Just pruritus (without any skin changes) is NOT sufficient for NIH skin score 1 or greater. (Q21) Skin
High
A patient had punctual plugging and had symptomatic relief to such an extent that he requires 
eye drops only 2 times a day. If you confirm that the punctal plugs fall out, the NIH eye score 
should be score 1. (Q29)
Eye
High If a patient lost vision in one eye because of chronic GVHD but is completely asymptomatic in the other eye, the NIH eye score is score 3. (Q36) Eye
Moderate Esophageal stricture or web, thrombocytopenia, pericardial effusion, and pleural effusion should be included in the global scoring system. (Q14) Global score
Moderate* (R)
The rule should be revised in scoring 3 for hidebound changes in only a small area (for example 
1% of legs). (Q17) Skin
Moderate Keratosis pilaris and hair involvement should be considered for calculating BSA. (Q19) Skin
Moderate Just nail and/or hair involvement is sufficient for NIH skin score 1. (Q20) Skin
Moderate Just hyperpigmentation and/or hypopigmentation of skin is sufficient for NIH skin score 1 or greater. (Q22) Skin
Moderate
A patient had punctual plugging and had symptomatic relief to such an extent that he requires 
eye drops only 2 times a day. If you confirm that the punctal plugs are still in the eyes, the NIH 
eye score should be score 2. (Q28)
Eye
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Topic 1: What are diagnostic and distinctive criteria for chronic GVHD?
Agreement level Agreed answer or controversial question Category
Moderate
A patient started special contact lenses for treatment of ocular GVHD and had symptomatic 




If a patient has diagnostic signs such as lichenoid changes but has no oral symptoms, the NIH 
mouth score should be score 1. (Q37) Mouth
Moderate We should consider superficial mucoceles that come and go when you determine the NIH mouth score. (Q41) Mouth
Controversial*
Performance status scoring is not incorporated into the NIH global scoring system. Should this 
be revised? (Q13) Global score
Controversial Ascites, eosinophilia, polymyositis, nephrotic syndrome, myasthenia gravis should be included in the global scoring system. (Q14) Global score
Controversial Nail involvement, hypopigmentation and hyperpigmentation should be considered for calculating BSA. (Q19) Skin
Controversial Should we consider excessive tearing as one form of GVHD in the NIH eye score? (Q34) Eye
Controversial A female patient is asymptomatic due to sexual inactivity and has moderate signs of genital GVHD. What is the NIH genital score? (Q67) Genital
Controversial A female patient tells you that she is asymptomatic but uses a dilator for her fixed moderate vaginal stricture. What is the NIH genital score? (Q68) Genital
Controversial Is vaginal dryness sufficient for NIH genital score 1 or greater? (Q69) Genital
Topic 5: Should manifestations not due to GVHD be included in the scoring?
Agreement level Agreed answer or controversial question Category
High* (R)
We should revise the current consensus that recommends rating all symptoms even if you do not 
think the symptoms are due to GVHD. (Q12) Overall
High
A patient has just been diagnosed with chronic GVHD in the mouth. If the patient has been 
using eye drops 3 times a day due to dry eye starting before transplant, the patient should NOT 
be scored for ocular chronic GVHD. (Q27)
Eye
High Joint tightness due to prior injury or avascular necrosis should be scored as 0 in the NIH joint score. (Q51) Joint/fascia
High
If a patient has chronic obstructive pulmonary disease (COPD) before transplant, we should 




A patient has mild loose stool and the colon biopsy is positive for GVHD. The patient also had 
10% weight loss as compared to one month ago, but you attribute the weight loss to poorly 
controlled steroid-induced diabetes. The NIH GI score should be score 2. (Q46)
GI
Moderate Dyspnea that you believe is due to steroid myopathy should be scored as 0. (Q59) Lung
Controversy
A patient uses eye drops 2 times a day due to dry eye prior to transplant. After transplant, he is 
diagnosed with chronic GVHD and increases the frequency of eye drops to 4 times a day due to 
worsening eye dryness. How do you rate the NIH eye score? (Q31)
Eye
Controversial
If other etiologies are confirmed for liver abnormalities (for example, hemochromatosis, viral 
hepatitis, leukemia invasion, drug side effect, or alcohol consumption), how do you rate the NIH 
liver score for patients with chronic GVHD? (Q50)
Liver
Topic 6: How should discrepancies between different evaluations be handled?
Agreement level Agreed answer or controversial question Category
High When you see hyperpigmentation and lichenoid in the same area, the Total Skin Score (Vienna score) is score 2. (Q25) Skin
High If eye symptoms differ between left and right eyes, I use the worse eye for rating the NIH eye score. (Q35) Eye
Moderate
When lung symptom scores differ from PFT scores, higher values are used for final lung scores. 
We should continue to use PFT scores to determine the lung score whenever PFT results are 
available even if the patient has no pulmonary symptoms. (Q60)
Lung
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Topic 1: What are diagnostic and distinctive criteria for chronic GVHD?
Agreement level Agreed answer or controversial question Category
Moderate If a patient has pulmonary symptoms with normal PFT, we should score 0 for the NIH lung score, since you are not sure whether the symptoms are due to GVHD. (Q61) Lung
Moderate The NIH genital score is score 3 for a female who has mild dyspareunia and severe signs on gynecological exam. (Q70) Genital tract
Controversial If the patient has extensive oral lichenoid changes but has only mild symptoms, how should we rate the NIH mouth score? (Q39) Mouth
Controversial How should we rate the NIH mouth score for moderate oral sensitivities without lichenoid changes or other signs of chronic GVHD? (Q38) Mouth
Controversial A patient has normal AST, ALT and bilirubin, but has elevated alkaline phosphatase (AP). You do not have isozyme information for AP. How do you rate the NIH liver score? (Q48) Liver
Topic 7: When the current NIH recommendations lack clarity or are silent about particularly clinical situations, how should they be scored?
Agreement level Agreed answer or controversial question Category
High Erectile dysfunction is NOT a symptom of genital GVHD. (Q64) Genital
Moderate
All types of eye drops should NOT be included when counting the frequency of eye drops for 
rating the NIH eye score (i.e., also include cyclosporine eye drop, steroid eye drop, antibiotic 
eye drops)? (Q32)
Eye
Moderate The same laboratory tests for NIH chronic GVHD (ie, ALT, AST, bilirubin and alkaline phosphatase) should be applied to staging of late acute GVHD in the liver. (Q47) Liver
Moderate We should score the genitals for men. (Q65) Genital tract
Controversial When you diagnose recurrent late acute GVHD or quiescent chronic GVHD, how many days of acute GVHD resolution are required before symptoms start again? (Q9) Subcategory of GVHD
Controversial What is the reference time point used for calculation of weight loss? (Q45) GI
Controversial If a patient doesn’t have PFTs results, how should we determine the NIH lung score? (Q63) Lung
Controversial Can the NIH genital score be completed without gynecological exam? (Q66) Genital
*
Questions that asked specifically whether the current NIH recommendations should be revised. (R) = Revision recommended by respondents. 
(NR) = Respondents recommended against revision.
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